- Home
- UNCY vs SNTI Comparison
UNCY vs SNTI Comparison
Compare UNCY & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- SNTI
- Stock Information
- Founded
- UNCY 2016
- SNTI 2016
- Country
- UNCY United States
- SNTI United States
- Employees
- UNCY N/A
- SNTI N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- SNTI Health Care
- Exchange
- UNCY Nasdaq
- SNTI Nasdaq
- Market Cap
- UNCY 71.8M
- SNTI 85.3M
- IPO Year
- UNCY 2021
- SNTI N/A
- Fundamental
- Price
- UNCY $0.62
- SNTI $3.34
- Analyst Decision
- UNCY Strong Buy
- SNTI Strong Buy
- Analyst Count
- UNCY 3
- SNTI 1
- Target Price
- UNCY $5.50
- SNTI $12.00
- AVG Volume (30 Days)
- UNCY 510.7K
- SNTI 226.4K
- Earning Date
- UNCY 05-16-2025
- SNTI 05-06-2025
- Dividend Yield
- UNCY N/A
- SNTI N/A
- EPS Growth
- UNCY N/A
- SNTI N/A
- EPS
- UNCY N/A
- SNTI N/A
- Revenue
- UNCY N/A
- SNTI N/A
- Revenue This Year
- UNCY N/A
- SNTI N/A
- Revenue Next Year
- UNCY $1,502.84
- SNTI N/A
- P/E Ratio
- UNCY N/A
- SNTI N/A
- Revenue Growth
- UNCY N/A
- SNTI N/A
- 52 Week Low
- UNCY $0.20
- SNTI $1.52
- 52 Week High
- UNCY $1.16
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- UNCY 51.83
- SNTI 45.11
- Support Level
- UNCY $0.59
- SNTI $3.10
- Resistance Level
- UNCY $0.66
- SNTI $3.47
- Average True Range (ATR)
- UNCY 0.03
- SNTI 0.43
- MACD
- UNCY -0.00
- SNTI -0.07
- Stochastic Oscillator
- UNCY 40.05
- SNTI 19.00
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.